• 1
    Filmus J, Capurro M & Rast J (2008) Glypicans. Genome Biol 9, 224.
  • 2
    Traister A, Shi W & Filmus J (2008) Mammalian Notum induces the release of glypicans and other GPI-anchored proteins from the cell surface. Biochem J 410, 503511.
  • 3
    Kreuger J, Perez L, Giraldez AJ & Cohen SM (2004) Opposing activities of Dally-like glypican at high and low levels of Wingless morphogen activity. Dev Cell 7, 503512.
  • 4
    Fico A, Maina F & Dono R (2011) Fine-tuning of cell signaling by glypicans. Cell Mol Life Sci 68, 923929.
  • 5
    Li F, Shi W, Capurro M & Filmus J (2011) Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling. J Cell Biol 192, 691704.
  • 6
    Tsuda M, Kamimura K, Nakato H, Archer M, Staatz W, Fox B, Humphrey M, Olson S, Futch T, Kaluza V, et al. (1999) The cell-surface proteoglycan Dally regulates Wingless signaling in Drosophila. Nature 400, 276280.
  • 7
    Song HH, Shi W, Xiang Y & Filmus J (2005) The loss of Glypican-3 induces alterations in Wnt signaling. J Biol Chem 280, 21162125.
  • 8
    Lum L, Yao S, Mozer B, Rovescalli A, Von Kessler D, Nirenberg M & Beachy PA (2003) Identification of hedgehog pathway components by RNAi in Drosophila cultured cells. Science 299, 20392045.
  • 9
    Capurro MI, Xu P, Shi W, Li F, Jia A & Filmus J (2008) Glypican-3 inhibits hedgehog signaling during development by competing with Patched for Hedgehog binding. Dev Cell 14, 700711.
  • 10
    Akiyama T, Kamimura Firkus C, Takeo S, Shimmi O & Nakato H (2008) Dally regulates Dpp morphogen gradient formation by stabilizing Dpp on the cell surface. Dev Biol 313, 408419.
  • 11
    Hartwig S, Hu MC, Cella C, Piscione T, Filmus J & Rosenblum ND (2005) Glypican-3 modulates inhibitory BMP2-SMAD signaling to control renal development in vivo. Mech Dev 122, 928938.
  • 12
    Yan D & Lin X (2007) Drosophila glypican Dally-like acts in FGF-receiving cells to modulate FGF signaling during tracheal morphogenesis. Dev Biol 312, 203216.
  • 13
    Gutierrez J & Brandan E (2010) A novel mechanism of sequestering FGF-2 by glypican in lipid rafts, allowing skeletal muscle differentiation. Mol Cell Biol 30, 16341649.
  • 14
    Feraly J, Shin HR, Bray F, Forman D, Mathers C & Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127, 28932917.
  • 15
    Forner A, Llovet JM & Bruix J (2012) Hepatocellular carcinoma. Lancet 379, 12451255.
  • 16
    Serste T, Barrau V, Ozenne V, Vullierme MP, Bedossa P, Farges O, Valla DC, Vilgrain V, Paradis V & Degos F (2012) Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology 55, 800806.
  • 17
    Marrero JA (2011) Modern diagnosis of hepatocellular carcinoma: utilization of liver biopsy and genomic markers. J Hepatol 50, 659661.
  • 18
    Hsu HC, Cheng W & Lai PL (1997) Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res 57, 51795184.
  • 19
    Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E & Filmus J (2003) Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125, 8190.
  • 20
    Wang XY, Degos F, Dubois S, Tessiore S, Allegretta M, Guttmann RD, Jothy S, Belghiti J, Bedossa P & Paradis V (2006) Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Human Pathol 37, 14351441.
  • 21
    Zhang L, Liu H, Sun L, Li N, Ding H & Zheng J (2011) Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study. Acta Histochem 114, 547552.
  • 22
    Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, Niki T, Shibahara J, Mori M, Makuuchi M, et al. (2005) The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 18, 15911598.
  • 23
    Coston WMP, Loera S, Lau SK, Ishizawa S, Jiang Z, Wu CL, Yen Y, Weiss LM & Chu PG (2008) Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol 32, 433444.
  • 24
    Wang F, Jing X, Wang T, Li G, Li T, Zhang Q, Huang Y, Li J, Wang Y, Gao Y, et al. (2012) Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm. Am J Clin Pathol 137, 937945.
  • 25
    Wang FH, Yip YC, Zhang M, Vong HT, Chan KI, Wai KC & Wen JM (2010) Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy. J Clin Pathol 63, 599603.
  • 26
    Libbrecht L, Severi T, Cassiman D, Vander Borght S, Pirenne J, Nevens F, Verslype C, van Pelt J & Roskans T (2006) Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 30, 14051411.
  • 27
    The International Consensus Group for Hepatocellular Neoplasia (2008) Pathologic diagnosis of early hepatocellular carcinoma: a report of the International Consensus Group for Hepatocellular Carcinoma. Hepatology 49, 658664.
  • 28
    Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK & Terracciano LM (2008) Glypican3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues. Am J Clin Pathol 129, 899906.
  • 29
    Mounajjed T, Zhang L & Wu TT (2012) Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms. Hum Pathol in press,
  • 30
    Lee L, Wang K, Li G, Xie Z, Wang Y, Xu J, Sun S, Pocalyko D, Bhak J, Kim C, et al. (2011) Liverome: a curated database of liver cancer-related gene signatures with self-contained context information. BMC Genomics 12, S3.
  • 31
    Di Tommaso L, Destro A, Seok JY, Balladore E, Terracciano L, Sangiovanni A, Iavarone M, Colombo M, Jang JJ, Yu E, et al. (2009) The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 50, 746754.
  • 32
    Di Tommaso L, Franchi G, Park YN, Fiamengo B, Destro A, Morenghi E, Montorsi M, Torzilli G, Tommasini M, Terracciano L, et al. (2007) Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 45, 725734.
  • 33
    Tremosini S, Forner A, Boix L, Vilana R, Bianchi L, Reig M, Rimola J, Rodriguez-Lope C, Ayuso C, Sole M, et al. (2012) Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Gut 61, 14811487.
  • 34
    Bruix J & Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53, 10201022.
  • 35
    EASL-EORTC (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56, 908943.
  • 36
    Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotodhda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, et al. (2009) Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 100, 14031407.
  • 37
    Yorita K, Takahashi N, Takai H, Kato A, Susuki M, Ishiguro T, Ohtomo T, Nagaike K, Kondo K, Chijiiwa K, et al. (2010) Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma. Liver Int 31, 120131.
  • 38
    Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, Tokita S, Iwanari H, Ito Y, Nakano K, et al. (2004) Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 64, 24182423.
  • 39
    Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, et al. (2003) Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 306, 1625.
  • 40
    Capurro M, Xiang YY, Lobe C & Filmus J (2005) Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 65, 62456254.
  • 41
    Clevers H & Nusse R (2012) Wnt/β-catenin signaling and disease. Cell 149, 11921204.
  • 42
    White BD, Chien AJ & Dawson DM (2012) Dysregulation of Wnt/β-catenin signaling in gastrointestinal tumors. Gastroenterology 142, 219232.
  • 43
    Polakis P (2012) Drugging Wnt signalling in cancer. EMBO J 31, 27372746.
  • 44
    Bengochea A, de Souza MM, Lefrancois L, Le Roux E, Galy O, Chemin I, Kim M, Wands JR, Trepo C, Hainaut P, et al. (2008) Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer 99, 143150.
  • 45
    Thompson MD & Monga PS (2007) Wnt/β-catenin signaling in liver health and disease. Hepatology 45, 12981305.
  • 46
    Li L, Jin R, Zhang X, Lv F, Liu L, Liu D, Liu K, Li N & Chen D (2012) Oncogenic activation of GPC3 by c-Myc in human hepatocellular carcinoma. Hepatology 56, 13801390.
  • 47
    Yan D, Wu Y, Feng Y, Lin SC & Lin X (2009) The core protein of glypican Dally-like determines its biphasic activity in wingless morphogen signaling. Dev Cell 17, 470481.
  • 48
    De Cat B, Muyldermans SY, Coomans C, Degeest G, Vanderschueren B, Creemers J, Biemar F, Peers B & David G (2003) Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements. J Cell Biol 163, 625635.
  • 49
    Capurro MI, Shi W, Sandal S & Filmus J (2005) Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma. J Biol Chem 280, 4120141206.
  • 50
    Gaughofer C, Sagmeister S, Schrottmaier W, Fischer C, Rodgarkia-Dara C, Mohr T, Stattner S, Bichler C, Kandioler D, Wrba F, et al. (2011) Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology 53, 854864.
  • 51
    Galli A, Roure A, Zeller R & Dono R (2003) Glypican 4 modulates FGF signalling and regulates dorsoventral forebrain patterning in Xenopus embryos. Development 130, 49194929.
  • 52
    Cabibbo G, Latteri F, Antonucci M & Craxi A (2009) Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroentol Hepatol 6, 159169.
  • 53
    Villanueva A, Minguez B, Forner A, Reig M & Llovet JM (2010) Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 61, 317328.
  • 54
    Ishiguro T, Sugimoto M, Kinoshita Y, Miyazaki Y, Nakano K, Tsunoda H, Sugo I, Ohizumi I, Aburatani H, Hamakubo T, et al. (2008) Anti-glypican-3 antibody as a potential antitumor agent for human liver cancer. Cancer Res 68, 98329838.
  • 55
    Nakano K, Orita T, Nezu J, Yoshino T, Ohizumi I, Sugimoto M, Furugaki K, Kinoshita Y, Ishiguro T, Hamakubo T, et al. (2008) Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun 378, 279284.
  • 56
    Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H & Philip PA (2011) A phase 1 study of GC33, a recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. J Clin Oncol 29(suppl), 4085.
  • 57
    Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, et al. (2006) Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 12, 26892697.
  • 58
    Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, et al. (2012) Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunological evidence and potential for improving overall survival. Clin Cancer Res 18, 36863696.
  • 59
    Zittermann SI, Capurro MI & Filmus J (2010) Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer 126, 12911301.
  • 60
    Feng M, Kim H & Ho M (2011) Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro. Int J Cancer 128, 22462247.